Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on CYTK stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Roanna Ruiz’s rating is based on several compelling factors. The recent data presented at the 2025 European Society of Cardiology Congress highlighted the significant advantages of Cytokinetics’ aficamten over metoprolol in treating obstructive hypertrophic cardiomyopathy (oHCM). The study showed a notable improvement in peak VO2, suggesting that aficamten could become a preferred first-line treatment for newly diagnosed symptomatic oHCM patients.
Additionally, the safety concerns associated with Bristol Myers Squibb’s mavacamten in nonobstructive HCM (nHCM) patients, such as reduced left ventricular ejection fraction and heart failure, may provide a competitive edge for aficamten. The differentiated therapeutic window of aficamten could offer significant advantages, especially in the challenging nHCM setting. These factors, combined with the positive market reaction, support the potential for aficamten to enhance Cytokinetics’ commercial prospects, justifying the Buy rating.
According to TipRanks, Ruiz is an analyst with an average return of -3.2% and a 43.82% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as United Therapeutics, Lantheus, and Aquestive Therapeutics.
In another report released yesterday, Jefferies also reiterated a Buy rating on the stock with a $80.00 price target.